Use of a Biofilm Antimicrobial Susceptibility Assay to Guide Antibiotic Therapy

Randomized Double Blind Controlled Trial of the Use of a Biofilm Antimicrobial Susceptibility Assay to Guide Antibiotic Therapy in Chronic Pseudomonas Aeruginosa Infected Cystic Fibrosis Patients

The purpose of this study is to determine whether choosing antibiotics based on a biofilm antimicrobial susceptibility assay rather than a conventional planktonic antimicrobial susceptibility assay to treat CF patients with chronic P. aeruginosa infection with an acute pulmonary exacerbation is a safe intervention that will result in improved microbiological and clinical outcomes and decrease markers of pulmonary inflammation.

Study Overview

• Status: Completed
• Conditions: Cystic Fibrosis
• Intervention / Treatment: Other: Conventional antimicrobial susceptibility testing; Other: Biofilm antimicrobial susceptibility testing

Detailed Description

Cystic fibrosis (CF) is the most common fatal genetic condition in the Caucasian population and affects over 3,000 Canadians. Respiratory failure caused by chronic pulmonary infection is the primary cause of death in CF patients. The improved life expectancy of CF patients in the past several decades is due in part to the more aggressive use of antibiotics in the treatment of respiratory infections. However, there is currently no antimicrobial susceptibility assay that can predict which antibiotics will result in improved patient outcomes. Since Pseudomonas aeruginosa is known to grow as a resistant biofilm in the CF lung, antimicrobial susceptibility testing based on biofilm growth of P. aeruginosa may lead to different antibiotic choices that significantly decrease the pulmonary bacterial density of P. aeruginosa. A biofilm antimicrobial susceptibility assay thus has the ability to change the way antibiotics are chosen to treat CF patients and result in improved lung function and longer lives for all CF patients.

• Study Type: Interventional
• Enrollment (Actual): 134
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada
      • BC Children's Hospital
    • Vancouver, British Columbia, Canada
      • St. Paul's Hospital
  • Ontario
    • Hamilton, Ontario, Canada
      • Hamilton Health Sciences
    • Toronto, Ontario, Canada
      • St. Michael's Hospital
    • Toronto, Ontario, Canada
      • The Hospital for Sick Children

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of CF based on the following: sweat chloride > 60 mEq/L or genotype with 2 identifiable mutations consistent with CF; and one or more clinical features consistent with CF
• Chronically infected with P. aeruginosa (>50% of respiratory specimens positive for P. aeruginosa in the 24 months prior to screening)
• Able to produce sputum (expectorated or induced)
• Able to reproducibility perform pulmonary function testing
• Written informed consent provided

Exclusion Criteria:

• Sputum culture negative for P. aeruginosa or with a density of less that 10^5 CFU/g at screening
• Sputum culture positive for Burkholderia cepacia at screening
• History of B. cepacia positive respiratory culture within 24 months prior to screening
• Use of antibiotics other than those prescribed by the principal investigator
• History of allergy (urticarial rash, diffuse erythroderma, serum sickness) to more than two groups of antibiotics (aminoglycosides, penicillins, cephalosporins, monobactams, macrolides, or quinolones) that are a therapeutic option
• History of anaphylaxis or other life threatening complication to any antibiotic in the six groups that are a therapeutic option
• Post lung transplantation or listed for lung transplantation
• Pregnancy
• A septic or clinically unstable patient
• Presence of a condition or abnormality that in the opinion of an investigator would compromise the safety of the patient or the quality of the data

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention Arm	Other: Biofilm antimicrobial susceptibility testing; Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
Active Comparator: Control Arm	Other: Conventional antimicrobial susceptibility testing; Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The proportion of patients in the intervention arm versus the control arm who have ≥ 3 log drop in colony forming units (CFUs) of P. aeruginosa in sputum.	Measured at day 0 and day 14 of antibiotic treatment and at the 1 month follow-up visit

Secondary Outcome Measures

Outcome Measure	Time Frame
The change in pulmonary function tests, including forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and maximal midexpiratory flow rate (FEF25-75) in the intervention arm versus the control arm	Measured at day 0, day 7, and day 14 of antibiotic treatment and at the 1 month follow-up visit
The time to subsequent acute pulmonary exacerbation in the intervention arm versus the control arm	1 year following the completion of antibiotic therapy
The change in the cumulative score on a quality of life questionnaire in the intervention arm versus the control arm	Measued at day 0 and day 14 of antibiotic treatment and at the 1 month follow-up visit
The change in the measurement of markers of pulmonary inflammation (neutrophil counts, neutrophil elastase and IL-8 levels in sputum) in the intervention arm versus the control arm.	Meaured at day 0 and day 14 of antibiotic treatment and at the 1 month follow-up visit

Collaborators and Investigators

• Sponsor: The Hospital for Sick Children
• Investigators: Principal Investigator: Valerie Waters, MD, The Hospital for Sick Children; Principal Investigator: Yvonne Yau, MD, The Hospital for Sick Children

Publications and helpful links

General Publications

• Yau YC, Ratjen F, Tullis E, Wilcox P, Freitag A, Chilvers M, Grasemann H, Zlosnik J, Speert D, Corey M, Stanojevic S, Matukas L, Leahy TR, Shih S, Waters V. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. J Cyst Fibros. 2015 Mar;14(2):262-6. doi: 10.1016/j.jcf.2014.09.013. Epub 2014 Oct 30.

Study record dates

Study Major Dates

• Study Start: November 1, 2008
• Primary Completion (Actual): March 1, 2014
• Study Completion (Actual): March 1, 2014

Study Registration Dates

• First Submitted: November 5, 2008
• First Submitted That Met QC Criteria: November 5, 2008
• First Posted (Estimate): November 6, 2008

Study Record Updates

• Last Update Posted (Estimate): April 4, 2014
• Last Update Submitted That Met QC Criteria: April 2, 2014
• Last Verified: April 1, 2014

More Information

Terms related to this study

• Keywords: pediatrics; Cystic fibrosis; Pseudomonas aeruginosa; biofilm; antibiotic susceptibility testing
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Disease Attributes; Infant, Newborn, Diseases; Genetic Diseases, Inborn; Pancreatic Diseases; Fibrosis; Disease Susceptibility; Cystic Fibrosis; Anti-Bacterial Agents; Anti-Infective Agents
• Other Study ID Numbers: 1000011132